Behavior
Conduct extensive pain, sensory, motor, and cognitive behavioral testing.
MD Biosciences provides comprehensive Parkinson’s disease animal models, including MPTP and 6-OHDA neurotoxin models, along with advanced genetic approaches. These models yield critical insights into neurodegeneration and pain, supporting the development of more effective therapies.
The Parkinson’s disease neurodegeneration assay utilizes primary neurons from rats to assess neuroprotection. After conditioning with alpha-synuclein, cultures are treated with test compounds and evaluated for the degeneration index. This endpoint is determined by comparing the neurite area and blebs.
The 6-hydroxydopamine (6-OHDA) Parkinson's rat model is a unilateral lesion model used to study damage to the Nigrostriatal pathway. 6-OHDA is delivered via stereotaxic injection into brain regions like the substantia nigra (SN), ventral tegmental area (VTA), or striatum, bypassing the blood-brain barrier to induce dopaminergic degeneration characteristic of Parkinson’s disease.
The MPTP Parkinson’s mouse model is commonly used to study Parkinson’s disease. MPTP, a lipophilic compound, crosses the blood-brain barrier and selectively targets dopaminergic neurons, similar to the 6-OHDA model. MPTP-induced animals exhibit motor abnormalities, making it an effective model for Parkinson’s research.
MD Biosciences offers comprehensive in vivo measures and endpoint assessments, delivering robust data packages to support critical research decisions in the evolving landscape of drug development and biomedical research.
Conduct extensive pain, sensory, motor, and cognitive behavioral testing.
Explore inflammatory and pain biomarkers in disease-specific tissues.
Characterize tissue and cellular changes in disease, pain, and neurodegeneration.